Methods for alleviating testicular pain

Details Methods for alleviating testicular pain Methods for alleviating testicular pain

2006-05-02

2010-10-12

Ford, Vanessa L. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S236100, C424S239100, C530S300000, C530S324000

Reexamination Certificate

active

07811586

ABSTRACT:
Method for alleviating testicular pain in a patient in need thereof. The method can comprise the step of locally administering a neurotoxin (e.g., a botulinum toxin) to at least one anatomical site selected from the group consisting of a testicle and a tissue associated with the testicle of the patient.

REFERENCES:
patent: 5427291 (1995-06-01), Smith
patent: 5670484 (1997-09-01), Binder
patent: 5674205 (1997-10-01), Pasricha et al.
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6139845 (2000-10-01), Donovan
patent: 6143306 (2000-11-01), Donovan
patent: 6235289 (2001-05-01), Aoki et al.
patent: 6265379 (2001-07-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306403 (2001-10-01), Donovan
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6328977 (2001-12-01), Donovan
patent: 6333037 (2001-12-01), Aoki et al.
patent: 6358513 (2002-03-01), Voet et al.
patent: 6365164 (2002-04-01), Schmidt
patent: 6372226 (2002-04-01), Aoki et al.
patent: 6395277 (2002-05-01), Graham
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6776991 (2004-08-01), Naumann
patent: 6869610 (2005-03-01), Aoki et al.
patent: 6887476 (2005-05-01), Aoki et al.
patent: 2004/0126380 (2004-07-01), Schmidt
patent: 2004/0180065 (2004-09-01), Schmidt
patent: 2005/0049175 (2005-03-01), Schmidt
patent: 2005/0112147 (2005-05-01), Schmidt
patent: 0 605 501 (1999-04-01), None
patent: WO 95/17904 (1995-07-01), None
Granitsiotis (European Urology, 45 (2004) 430-436).
Cakmak et al (Urol. Res. (2003), 31:352-354).
Forte et al (Chir Ital. Jan.-Feb. 2003;55(1):145-7)(Abstract only).
Mense (J Neurol (2004) 251[Suppl 1]:1/1-1/7).
Freund et al, Journal of Pain, vol. 4, No. 3 (Apr. 2003), pp. 159-165.
Cremaster muscle, Dictionary.com, http://dicitionary.reference.com.
Orchitis, Dictionary.com, http://dicitionary.reference.com.
Spermatic cord, Dictionary.com, http://dicitionary.reference.com.
Fisher et al (Human Reproduction, 2003, vol. 18, No. 7, p. 1383-1394).
Bigalke H., et al.,Botulinum A Clostridial toxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture, Brain Research 360;318-324:1985.
Bigalke H., et al.,Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord, Naunyn-Schmiedeberg's Arch Pharmacol 316;244-251:1981.
Binz T. et al.,The Complete Sequence of Botulinum Clostridial toxin Type A and Comparison with Other Clostridial toxins, J Biological Chemistry 265(16);9153-9158:1990.
Boyd R.S. et al., The effect of botulinum Clostridial toxin-B on insulin release from a ∃-cell line,Mov Disord, 10(3):376:1995.
Boyd R.S. et al., The insulin secreting ∃-cell line, HIT-15, contains SNAP-25 which is a target for botulinum Clostridial toxin-A,Mov Disord, 10(3):376:1995.
Cakmak et al. (2003) Urol Res 31:352-354.
Dykstra, D.D., et al,Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: A double-blind study, Arch Phys Med Rehabil Jan. 1990;71:24-6.
Gonelle-Gispert, C., et al.,SNAP-25a and —25b isoforms are both expressed in insulin-secreting cells and can function in insulin secretion, Biochem J. 1;339 (pt 1):159-65:1999.
Granitsiotis et al., European Urology (2004) 45:430-436, at p. 431.
Habermann E., et al.,Tetanus Toxin and Botulinum A and C Clostridial toxins Inhibit Noradrenaline Release From Cultured Mouse Brain, J Neurochem 51(2);522-527:1988.
Habermann E.,Inhibition by Tetanus and Botulinum A Toxin of the release of [3H]Noradrenaline and [3H]GABA From Rat Brain Homogenate, Experientia 44;224-226:1988.
Habermann,125I-labelled Clostridial toxin from clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord, Nauny-Schmiedeberg's Arch. Pharmacol. 1974; 281, 47-56.
Harrison's Principles of Internal Medicine(1998), edited by Anthony Fauci et al., 14thedition, published by McGraw Hill.
Coffield, et al., Eds. Jankovic J. et al.,Therapy With Botulinum Toxin, Marcel Dekker, Inc., (1994), p. 5.
Kohl A., et al.,Comparison of the effect of botulinum toxin A(BOTOX(R))with the highly-purified Clostridial toxin(NT 201)in the extensor digitorum brevis muscle test, Mov Disord 2000;15(Suppl 3):165.
Marjama-Lyons, J., et al.,Tremor-Predominant Parkinson's Disease, Drugs & Aging 16(4);273-278:2000.
Moyer E et al.,Botulinum Toxin Type B: Experimental and Clinical Experience, being chapter 6, pp. 71-85 of “Therapy With Botulinum Toxin”, edited by Jankovic, J. et al. (1994), Marcel Dekker, Inc.
Naumann M., et al.,Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions, European J. Neurology 6 (Supp 4): S111-S115:1999.
Pearce, L.B.,Pharmacologic Characterization of Botulinum Toxin For Basic Science and Medicine, Toxicon 35(9);1373-1412 at 1393.
Ragona, R.M., et al.,Management of parotid sialocele with botulinum toxin, The Laryngoscope 109:1344-1346:1999.
Rohrbach S., et al.,Botulinum toxin type A induces apoptosis in nasal glands of guinea pigs, Ann Otol Rhinol Laryngol Nov. 2001;110(11):1045-50.
Rohrbach S., et al.,Minimally invasive application of botulinum toxin type A in nasal hypersecretion, J Oto-Rhino-Laryngol Nov.-Dec. 2001;63(6):382-4.
Sanchez-Prieto, J., et al.,Botulinum Toxin A Blocks Glutamate Exocytosis From Guinea Pig Cerebral Cortical Synaptosomes, Eur J. Biochem 165;675-681:1987.
Schantz E.J., et alPreparation and characterization of botulinum toxin type A for human treatment(in particular pp. 44-45), being chapter 3 of Jankovic, J., et al,Therapy with Botulinum Toxin, Marcel Dekker, Inc (1994).
Schantz, E.J., et al,Properties and use of Botulinum toxin and Other Microbial Clostridial toxins in Medicine, Microbiol Rev. 56;80-99:1992.
Singh,Critical Aspects of Bacterial Protein Toxins, pp. 63-84 (chapter 4) of Natural Toxins II, edited by B.R. Singh et al., Plenum Press, New York (1996).
Sloop, R., et al.,Neurology, 1998 (48), pp. 249-253.
Weigand et al,125I-labelled botulinum A Clostridial toxin:pharmacokinetics in cats after intramuscular injection, Nauny-Schmiedeberg's Arch. Pharmacol. 1976; 292, 161-165.
Westhoff et al. (2002) Naunyn Schmiedebergs Arch Pharmacol 365(Suppl) 2:R 48.
Levine, et al.,Microsurgical denervation of the spermatic cord as primary surgical treatment of chronic orchialgia, Journal of Urology, vol. 165, No. 6, Jun. 2001, pp. 1927-1929 (Abst).
Schurch, B., et al.,Botox in urology: a new treatment modality without limitations? Eau Update Series, vol. 2, No. 4, Dec. 2004, pp. 170-178 (Abst).
Mayo Clinic,Retractile testicle, 1998-2009 (web page www.MayoClinic.com).

Affiliated with

Also associated with

Rating

Methods for alleviating testicular pain does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for alleviating testicular pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for alleviating testicular pain will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4206965